Marcel de Leeuw

Mr. Marcel de Leeuw

MRM Health, Gent, Flanders, Belgium
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
TMTalat H. Malik
Talat H. Malik
PLPeter J. Lavin
Peter J. Lavin
EJElena Goicoechea de Jorge
Elena Goicoechea de Jorge
KVKatherine A. Vernon
Katherine A. Vernon
KRKirsten L. Rose
Kirsten L. Rose
MPMatthew C. Pickering
Matthew C. Pickering
Controlled activation of the complement system, a key component of innate immunity, enables destruction of pathogens with minimal damage to host tissue. Complement factor H (CFH), which inhibits complement activation, and five CFH-related proteins (CFHR1–5) compose a family of structurally related molecules. Combined deletion of CFHR3 and CFHR1 is common and confers a protective effect in IgA nephropathy. Here, we report an autosomal dominant complement-mediated GN associated with abnormal increases in copy number across the CFHR3 and CFHR1 loci. In addition to normal copies of these genes, affected individuals carry a unique hybrid CFHR3–1 gene. In addition to identifying an association between these genetic observations and complement-mediated kidney disease, these results provide insight into the protective role of the combined deletion of CFHR3 and CFHR1 in IgA nephropathy.

15 May 2015 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
PDF file
ACAoife Corrigan
Aoife Corrigan
MLMarcel de Leeuw
Marcel de Leeuw
SPStéphanie Penaud-Frézet
Stéphanie Penaud-Frézet
DDDiliana Dimova
Diliana Dimova
RMR. A. Murphy
R. A. Murphy
This study focused on identifying reproducible effects of dietary supplementation with a mannan oligosaccharide (MOS) on the broiler cecal bacterial community structure and function in a commercial production setting. Two separate trials, each with a control and a supplemented group, were carried out in the same commercial location and run concurrently. Approximately 10,000 birds from the same commercial hatchery were mirror imaged into each of four commercial broiler sheds and fed either a control or supplemented diet. Cecal contents were obtained on days 7, 21, and 35 posthatch from 12 randomly caught broilers from each group. Bacterial pyrosequencing was performed on all samples, with approximately 250,000 sequences obtained per treatment per time point. The predominant phyla identified at all three time points in both trials were Firmicutes , Bacteroidetes , Proteobacteria , Actinobacteria , and Tenericutes , representing >99% of all sequences. MOS supplementation altered the bacterial community composition from 7 days supplementation through 35 days supplementation. Bacteroidetes appeared to be replacing Firmicutes as a result of supplementation, with the most noticeable effects after 35 days. The effects of supplementation were reproducible across both trials. PICRUSt was used to identify differences between the functional potentials of the bacterial communities as a result of MOS supplementation. Using level 3 KEGG ortholog function predictions, differences between control and supplemented groups were observed, with very strong segregation noted on day 35 posthatch in both trials. This indicated that alterations of bacterial communities as a result of MOS are likely to alter the functional capability of the cecum.

20 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
IPIris Pinheiro
Iris Pinheiro
Aurora BarberáAurora Barberá
Aurora Barberá
ISImmaculada Raurell Saborit
Immaculada Raurell Saborit
FEFederico Estrella
Federico Estrella
MLMarcel de Leeuw
Marcel de Leeuw
SASalvador Augustin
Salvador Augustin
The gut microbiome has a recognized role in Non-alcoholic fatty liver disease (NAFLD) and associated comorbidities such as Type-2 diabetes and obesity. Stool transplantation has been shown to improve disease by restoring endothelial function and insulin signaling. However, more patient-friendly treatments are required. The present study aimed to test the effect of a defined bacterial consortium of nine gut commensal strains in two in vivo rodent models of Non-alcoholic steatohepatitis (NASH): a rat model of NASH and portal hypertension (PHT), and the Stelic animal (mouse) model (STAM™). In both studies the consortium was administered orally q.d. after disease induction. In the NASH rats, the consortium was administered for 2 weeks and compared to stool transplant. In the STAM™ study administration was performed for 4 weeks, and the effects compared to vehicle or Telmisartan at the stage of NASH/early fibrosis. A second group of animals was followed for another 3 weeks to assess later-stage fibrosis. In the NASH rats, an improvement in PHT and endothelial function was observed. Gut microbial compositional changes also revealed that the consortium achieved a more defined and richer replacement of the gut microbiome than stool transplantation. Moreover, liver transcriptomics suggested a beneficial modulation of pro-fibrogenic pathways. An improvement in liver fibrosis was then confirmed in the STAM™ study. In this study, the bacterial consortium improved the NAFLD activity score, consistent with a decrease in steatosis and ballooning. Serum cytokeratin-18 levels were also reduced. Therefore, administration of a specific bacterial consortium of defined composition can ameliorate NASH, PHT, and fibrosis, and delay disease progression.

19 May 2020 in Exploratory Research and Hypothesis in Medicine
Verified
Journal Article
Open access
PDF file
MLMarcel de Leeuw
Marcel de Leeuw
MDManuel X. Duval
Manuel X. Duval
Microbiota are thought to play a role in the development of gastric cancer (GC). Several studies have put forward putatively carcinogenic species in addition to Helicobacter pylori but are not in perfect alignment, possibly due to variable parameters in the experiments. Meta-analyses on this subject have not been published so far. Therefore, there is a lack of clinical guidance beyond H. pylori eradication therapy.

30 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MLMarcel de Leeuw
Marcel de Leeuw
MDManuel X. Duval
Manuel X. Duval
Background: Inflammatory bowel disease (IBD) is a set of conditions characterized by non-infectious chronic inflammation of the gastrointestinal tract. These primarily include Crohn’s disease (CD), ulcerative colitis (UC) and indeterminate colitis. Fecal microbiota transplantation (FMT) has proven to be an effective treatment for some patients with active UC. There is currently no procedure allowing to predict the patients’ response and to select the most adequate donor(s). Aim: Investigate microbiome characteristics in association with responder/non-responder status and develop selection criteria for donor samples to be used for UC FMT. Methods: Available UC longitudinal FMT microbiome data sets were in part combined and reanalyzed, with focus on species level changes in the microbiota, using state-of-the-art 16S analysis routines. Results: We predicted antibiotic resistance to be higher in non-responders (p=0.0064). Microbiomes of UC FMT responder donors have higher phylogenetic diversity (p=0.0026) and a higher proportion of facultative anaerobes (p=3.3E-5) as compared to non-responder donors. We predicted succinate and histamine to be increased in non-responder donors and non-responders, respectively. Sialic acid catabolism was also predicted to be increased in non-responder donors. Tryptamine and indole-3-acetaldehyde were predicted to be increased in responder donors. Conclusions: Our findings contribute to the establishment of selection criteria for UC FMT donor samples and composition guidelines for future synthetic microbial communities. Our results suggest that oxidative stress resistant facultative anaerobes are important for the establishment of an anaerobic environment and a successful UC FMT therapy. Several metabolites can be tested for additional optimization or prioritization of stool bank samples for UC FMT. Our results question the usefulness of antibiotics based preparation of the gut, prior to FMT.

11 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MLMarcel de Leeuw
Marcel de Leeuw
MDManuel X. Duval
Manuel X. Duval
Background: Gut microbiota (GM) composition has been associated with acute Graft-versus-Host Disease (aGvHD), however, current knowledge is insufficient to target the GM. Methods: A relevant series of microbiome data sets were combined and reanalyzed, with resolution of species level changes in the GM. Results: GM composition was found strongly correlated with aGvHD status after one month post stem cell infusion (R2=0.51). The predicted average biological safety level, indicative of antibiotic resistance, was found increased in aGvHD cases (p=1.6E-4). Using in silico modelling, we formulated a probiotic composition putatively competing with mortality and aGvHD associated species. Implications: Supplementation with Bifidobacterium longum and Bifidobacterium breve is proposed as a prophylactic treatment alongside with prebiotics and an adapted antibiotics course.